Tuesday, April 16, 2024

Assessing the Economic Impact of Adverse Drug Events: A Review of Methods

Similar articles

Adverse drug events (ADEs) represent a significant safety, quality of care, and economic issue. They often occur during hospital stays, thus necessitating an accurate quantification of their associated costs. A recent review has sought to investigate the methods used to calculate these costs and characterize their nature.

To identify these methods, a systematic literature review was conducted across Medline, Web of Science, and Google Scholar. The review focused on original articles published in English and French from 2017 to 2022. Included were economic evaluations related to inpatients.

Adverse Drug Events

Challenges in Assessing the Costs of Adverse Drug Events

From a pool of 127 studies, 20 were analyzed. The findings revealed a high degree of heterogeneity in terms of cost nature, methods used, values obtained, and the chosen time horizon. Notably, only a limited number of studies took into account non-medical (10%), indirect (20%), and opportunity costs (5%). A total of ten different methods for assessing the cost of ADEs were identified, with nine studies failing to explain their value derivation process.

The review concluded that there is currently no consensus in the literature on how to assess the costs of ADEs. This is largely due to the heterogeneity of contexts and the selection of differing economic perspectives. This study provides a much-needed overview of the existing literature, offering a robust starting point for future studies and method implementation.


Orijinal Article DOI: 10.1186/s13561-024-00481-y

Original title: Evaluating the costs of adverse drug events in hospitalized patients: a systematic review

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article